Literature DB >> 10831073

T-cell-specific expression of kinase-defective Eph-family receptor protein, EphB6 in normal as well as transformed hematopoietic cells.

M Shimoyama1, H Matsuoka, A Tamekane, M Ito, N Iwata, R Inoue, K Chihara, A Furuya, N Hanai, T Matsui.   

Abstract

Although most kinase-defective growth factor receptor proteins are associated with pathogenic conditions, a kinase-defective Eph-family receptor protein, EphB6, is expressed in normal human tissues. We generated monoclonal antibodies specific for human EphB6 to characterize its expression on human hematopoietic cells. A very small population of normal human peripheral white blood cells (0.57 +/- 0.07%, n = 12) expressed EphB6. The EphB6-positive cells were CD2+, CD7+, CD3+ and CD4+ or CD8+ lymphocytes, but they did not express CD19 or CD11b. In human bone marrow, only 1.5 +/- 0.19% of lymphocytes expressed EphB6. Compared with the expression in peripheral lymphocytes, prominent expression of EphB6 protein was demonstrated in CD4+CD8+ double-positive mouse thymocytes. The T-cell lineage-specific expression was strictly conserved in human leukemia/lymphoma cells. Among T-cell-derived leukemia cells, the expression level of EphB6 seemed to decrease with maturation of the cells. These results suggest that EphB6 expression is regulated in T-cell development.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10831073     DOI: 10.3109/08977190009003234

Source DB:  PubMed          Journal:  Growth Factors        ISSN: 0897-7194            Impact factor:   2.511


  6 in total

1.  EphB6 crosslinking results in costimulation of T cells.

Authors:  Hongyu Luo; Guang Yu; Yulian Wu; Jiangping Wu
Journal:  J Clin Invest       Date:  2002-10       Impact factor: 14.808

2.  EphB6-null mutation results in compromised T cell function.

Authors:  Hongyu Luo; Guang Yu; Johanne Tremblay; Jiangping Wu
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

3.  Alterations in the thymocyte phenotype of EphB-deficient mice largely affect the double negative cell compartment.

Authors:  David Alfaro; Juan José Muñoz; Javier García-Ceca; Teresa Cejalvo; Eva Jiménez; Agustín Zapata
Journal:  Immunology       Date:  2008-04-04       Impact factor: 7.397

4.  EphA3 as a target for antibody immunotherapy in acute lymphoblastic leukemia.

Authors:  S Charmsaz; F Al-Ejeh; T M Yeadon; K J Miller; F M Smith; B W Stringer; A S Moore; F-T Lee; L T Cooper; C Stylianou; G T Yarranton; J Woronicz; A M Scott; M Lackmann; A W Boyd
Journal:  Leukemia       Date:  2016-12-06       Impact factor: 11.528

Review 5.  Protein Tyrosine Kinases: Their Roles and Their Targeting in Leukemia.

Authors:  Kalpana K Bhanumathy; Amrutha Balagopal; Frederick S Vizeacoumar; Franco J Vizeacoumar; Andrew Freywald; Vincenzo Giambra
Journal:  Cancers (Basel)       Date:  2021-01-07       Impact factor: 6.639

6.  The EphB6 receptor is overexpressed in pediatric T cell acute lymphoblastic leukemia and increases its sensitivity to doxorubicin treatment.

Authors:  Amr El Zawily; Emily McEwen; Behzad Toosi; Frederick S Vizeacoumar; Tanya Freywald; Franco J Vizeacoumar; Andrew Freywald
Journal:  Sci Rep       Date:  2017-11-07       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.